|
|
| | Andecaliximab Basic information |
| Product Name: | Andecaliximab | | Synonyms: | Andecaliximab;Research Grade Andecaliximab(DHD06801);GS-5745;Research Grade Andecaliximab | | CAS: | 1518996-49-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Andecaliximab Structure]() |
| | Andecaliximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Andecaliximab Usage And Synthesis |
| Uses | Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2]. | | in vivo | Andecaliximab improves T-cell receptor (TCR) diversity (decreased clonality) within tumor-infiltrating T-cell[1].
Andecaliximab (20 mg/kg; i.p. once) shows the antifibrotic efficacy in a humanized NSG mouse model of idiopathic pulmonary fibrosis[2]. | Animal Model: | Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF[2] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; 20 mg/kg, once a week for once | | Result: | Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations. |
| | References | [1] Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
[2] Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. DOI:10.1164/rccm.201910-1977OC |
| | Andecaliximab Preparation Products And Raw materials |
|